Naveen Yarlagadda
Researcher
University of Arkansas for Medical Sciences
faculty
Research Areas
Links
Is this your profile? Verify and claim your profile
Biography and Research Information
OverviewAI-generated summary
Naveen Yarlagadda's research focuses on multiple myeloma, a type of blood cancer. His work has investigated the clinical implications of minimal residual disease (MRD) negativity, a measure of the amount of cancer remaining after treatment. Yarlagadda has examined the significance of persistent bone marrow MRD as a high-risk feature and the outcomes of tandem autologous stem cell transplantation in patients with persistent MRD after their first transplant. He has also contributed to understanding the complications associated with CD38-targeting monoclonal antibody therapies in multiple myeloma through meta-analyses. Additionally, his research has explored the relationship between phenotypic markers identified by flow cytometry and disease progression in monoclonal gammopathy of unknown significance. Yarlagadda has published 21 papers with an h-index of 5 and has collaborated with researchers at the University of Arkansas for Medical Sciences, including Sravani Gundarlapalli, Guido Tricot, Erming Tian, and Sharmilan Thanendrarajan.
Metrics
- h-index: 5
- Publications: 21
- Citations: 392
Selected Publications
- Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma (2022) DOI
- Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: A meta-analysis of randomized control trials (2021) DOI
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma (2021) DOI
Collaborators
Researchers in the database who share publications
Similar Researchers
Based on overlapping research topics